An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SQZ Biotechnologies to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13,and Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26. Presentation times and webcast information are available below.
PRESENTATION DETAILS
Wednesday, April 13 21st Annual Needham Virtual Healthcare Conference 9:30-10:10 am ET Webcast
Tuesday, April 26 Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit
10:00-10:25 am ET Webcast
Conference webcast details and the company’s most recent corporate overview presentation will be available on the Investors section of the SQZ website.
About SQZ Biotechnologies SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.
spun out of mit, sqz biotechnologies is developing the next generation of cell therapies, using its propriety technology to harness the power of the patient's immune system to combat disease. sqz: empower cells to change lives.
